Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 2 67 / https://doi.org/10.3332/ecancer.2008.67

Research

The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial

Background: We have previously reported the favourable effect of transdermal estradiol (E2), relative to oral conjugated equine oestrogen (CEE), on ultrasensitive C-reactive protein after 12 months of treatment in a retinoid-placebo controlled two-by-two randomized breast cancer prevention trial (Decensi A et al (2002) Circulation 106 10 1224–8). Here, we investigate the changes in lipids and clotting profile in patients of the same trial.

Methods and results: Recent post-menopausal women were randomised to either oral CEE 0.625 mg/day and placebo (n = 55), CEE and fenretinide 200 mg/day (n = 56), transdermal E2 50 mg/day and placebo (n = 59) or E2 and fenretinide 200 mg/day (n = 56). Sequential medroxyprogesterone acetate 10 mg/day was given in each group. After 12 months, there was a statistically significant effect of the route of administration of hormone replacement therapy (HRT) on fibrinogen levels; the median percentage change being -5.7% with CEE and -1.1% with E2 (p = 0.012). Total cholesterol decreased in all arms (p < 0.0001). HDL-C decreased significantly with transdermal E2 (p = 0.006) compared to oral CEE and with fenretinide relative to placebo (p<0.001). Triglycerides exhibited an opposite modulation in the HRT route, with a 21.4% median increase with oral CEE and an 8.6% reduction with transdermal E2 (p < 0.0001). Antithrombin-III showed a 4% borderline significant reduction in the fenretinide arm relative to placebo, irrespective of the HRT administration route (p = 0.055).

Conclusions: Our data indicate that transdermal E2 may be preferable to oral CEE based on its safer cardiovascular risk profile. Fenretinide modified some cardiovascular risk biomarkers and confirmed a safer profile compared to other retinoids.

Keywords: biological markers breast cancer prevention CHD fenretinide HRT

Categories:

Lung & pleura

Loading Article Metrics ... Please wait

Related articles

Short Communication: COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?

Abstract | Full Article | PDF Published: 30 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1023

Review: Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence

Abstract | Full Article | PDF Published: 27 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1022

Clinical Study: Prospective study to assess the survival outcomes of planned irradiation of ipsilateral subventricular and periventricular zones in glioblastoma

Abstract | Full Article | PDF Published: 26 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1021

Research: Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population

Abstract | Full Article | PDF | Español Published: 24 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1020

Clinical Study: Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer

Abstract | Full Article | PDF Published: 09 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1019



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation